US 7291603
Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
granted A61PA61P35/00
Quick answer
US patent 7291603 (Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations) held by PTC THERAPEUTICS, INC. expires Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Tue Nov 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61P, A61P35/00